Amir T. Fathi, MD, presents a multicenter retrospective cohort study demonstrating that intensive chemotherapy plus quizartinib was associated with superior 1-year overall survival (93% vs 78%; adjusted HR, 0.19) and event-free survival compared with intensive chemotherapy plus midostaurin in patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.
Wojciech Jurczak, MD, PhD, reviews EHA 2026 data supporting continuous zanubrutinib as a frontline treatment option for chronic lymphocytic leukemia, including findings from a matching-adjusted indirect comparison with ibrutinib.
Charu Aggarwal, MD, MPH, discusses planned interim results from the phase 2b TRITON trial evaluating tremelimumab plus durvalumab and chemotherapy versus pembrolizumab plus chemotherapy in patients with previously untreated metastatic non–small cell lung cancer harboring STK11, KEAP1, and/or KRAS mutations.
Ibrahim Aldoss, MD, discusses updated phase 1 results from the SNDX-5613-0708 study of revumenib plus intensive chemotherapy in patients with newly diagnosed AML harboring KMT2A, NPM1, or NUP98 alterations.
Rapid readout: New-onset AFib in CLL links to higher stroke, bleeding, heart failure, and care use; real-world data hints zanubrutinib lowers risk.
This presentation shows that the next-generation BTK inhibitor zanubrutinib demonstrates increasingly durable long-term survival and progression-free benefits compared with ibrutinib and acalabrutinib in previously untreated chronic lymphocytic leukemia, supporting its use as a preferred frontline therapy when direct comparative trial data are unavailable.
Ryan Jacobs, MD, discusses real-world data showing that first-line zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in patients with CLL/SLL.
Seven-year data show lorlatinib keeps ALK+ lung cancer controlled, with durable brain protection, stable safety, and clues to early resistance.
Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.
Michael Fradley, MD, discusses real-world data linking atrial fibrillation with increased cardiovascular and health care utilization burden in CLL/SLL, along with exploratory findings for first-line BTK inhibitors.
Jiong Wu, MD, PhD, discusses phase 3 PANKU-Breast02 findings showing that izalontamab brengitecan improved progression-free and overall survival vs chemotherapy in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer.
Nilanjan Ghosh, MD, reviews phase 3 data showing that tafasitamab plus lenalidomide and R-CHOP improved progression-free survival vs R-CHOP alone in patients with newly diagnosed high-risk DLBCL.
Peter Voorhees, MD, presents phase 3 MonumenTAL-3 data supporting talquetamab plus daratumumab, with or without pomalidomide, as a potential new standard for early relapsed/refractory multiple myeloma.
This presentation presents the first global clinical trial results evaluating the investigational bispecific antibody pumitamig combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer.
Phase II data show Silevertinib boosts responses and brain control in treatment‑naive EGFR non‑classical NSCLC, with manageable rash/diarrhea.
This presentation details results from the global Phase 3 FIGHT-302 trial, which evaluated pemigatinib compared to standard chemotherapy for patients with advanced or metastatic cholangiocarcinoma containing specific genetic rearrangements.
This phase 1b analysis from the ELEVATE study evaluated the combination of elacestrant and capivasertib in patients with ER-positive, HER2-negative advanced breast cancer whose tumors harbored alterations in the PI3K/AKT pathway. The combination demonstrated a manageable safety profile with no new safety concerns and showed encouraging antitumor activity, including durable disease control across a heavily pretreated population. These findings support further investigation of this all-oral regimen as a strategy to simultaneously target endocrine resistance and PI3K/AKT pathway–driven disease.
David M. Waterhouse, MD, MPH, reviews real-world claims data suggesting substantial underdiagnosis of Lambert-Eaton myasthenic syndrome among patients with small cell lung cancer and the need for improved recognition in oncology practice.
Jae Park, MD, discusses findings from the FELIX study showing that obecabtagene autoleucel demonstrated clinically meaningful activity and a manageable safety profile in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, including those with extramedullary disease at lymphodepletion.
Timothy Cloughesy, MD, presents updated INDIGO data showing that vorasidenib provides durable progression-free survival benefit and delays subsequent intervention in patients with IDH-mutant grade 2 glioma.
This presentation details results from the phase 3 SUCCESSOR-2 clinical trial evaluating the combination of oral mezigdomide, carfilzomib, and dexamethasone against carfilzomib and dexamethasone alone. The study focused on patients with relapsed or refractory multiple myeloma who had previously been exposed to specific standard therapies. Findings indicate that adding mezigdomide significantly improves progression-free survival across all prespecified patient subgroups while presenting a predictable and manageable safety profile.
Barbara Burtness, MD, presents OrigAMI-4 cohort 1 data showing that subcutaneous amivantamab produced deep and durable antitumor activity with a manageable safety profile in previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Rapid readout: sevabertinib delivers high, durable responses in HER2‑mutant advanced NSCLC, with manageable diarrhea and strong frontline benefit signals.
Mark Socinski, MD, highlights Stage 1 PRESERVE-003 data showing chemotherapy-free gotistobart improved survival and durable responses vs docetaxel in previously treated metastatic squamous NSCLC.
The HARMONi-6 study evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non–small cell lung cancer. The combination with ivonescimab demonstrated a meaningful overall survival advantage across key patient subgroups while maintaining a manageable and generally comparable safety profile. These findings support ivonescimab plus chemotherapy as a promising new frontline treatment option for this patient population
Marlana Orloff, MD, reviews primary OptimUM-02 data showing darovasertib plus crizotinib significantly improved progression-free survival and response rates versus investigator’s choice in first-line HLA-A2–negative metastatic uveal melanoma, with overall survival data not yet mature.
Rapid readout: Real-world lifileucel TIL shows 44% responses in metastatic melanoma, favoring early referral and manageable IL-2 toxicity.
Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer.
This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequently observed but generally low grade, short in duration, and manageable with standard supportive care and dose modifications. Findings also suggest that prior therapies and drug exposure levels may influence the risk of more severe diarrhea, providing useful context for clinical management.
